دورية أكاديمية
Severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab.
| العنوان: | Severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab. |
|---|---|
| المؤلفون: | Corral IS; Dermatology Clinic, Santa Casa de Misericórdia de São Paulo, São Paulo(SP), Brazil., Freitas TH, Aquino RT, Koller DA, Magliari ME, Muller H |
| المصدر: | Anais brasileiros de dermatologia [An Bras Dermatol] 2013 Jul-Aug; Vol. 88 (4), pp. 639-42. |
| نوع المنشور: | Case Reports; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier España, S.L Country of Publication: Spain NLM ID: 0067662 Publication Model: Print Cited Medium: Internet ISSN: 1806-4841 (Electronic) Linking ISSN: 03650596 NLM ISO Abbreviation: An Bras Dermatol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Barcelona, Spain : Elsevier España, S.L. Original Publication: Rio De Janeiro : Sociedade Brasileira de Dermatologia |
| مواضيع طبية MeSH: | Drug Resistance, Multiple*, Antibodies, Monoclonal, Murine-Derived/*administration & dosage , Immunologic Factors/*administration & dosage , Pemphigus/*drug therapy, Adult ; Glucocorticoids/administration & dosage ; Humans ; Male ; Prednisone/administration & dosage ; Rituximab ; Time Factors ; Treatment Outcome |
| مستخلص: | Pemphigus vulgaris is an autoimmune bullous disease whose therapy is based on systemic corticosteroids, with or without immunosuppressants. Rituximab is a chimeric monoclonal antibody of the IgG class, directed at a specific CD20 B cell surface antigen, used in pemphigus vulgaris empirically since 2002, with success in 90% of the cases and long periods of remission. Male patient, 33 years old, diagnosed with pemphigus vulgaris, confirmed by histopathology and direct immunofluorescence. He was treated for seven months with numerous treatments, including immunosuppressive drugs, with an unsatisfactory response, until he had complete remission with the use of rituximab. During a 34-month follow-up period, the patient presented a slight clinical relapse, which was successfully controlled with prednisone in a daily dose of 120 mg, soon reduced to 20mg. |
| References: | Arch Dermatol. 2007 Aug;143(8):1033-8. (PMID: 17709662) Dermatol Clin. 2011 Oct;29(4):571-5. (PMID: 21925000) Arch Dermatol. 2012 Jun;148(6):734-9. (PMID: 22351790) Dermatology. 2007;214(4):275-7. (PMID: 17460396) Rheumatol Int. 2008 Jan;28(3):205-15. (PMID: 17957371) N Engl J Med. 2007 Aug 9;357(6):605-7. (PMID: 17687137) J Dtsch Dermatol Ges. 2008 May;6(5):366-73. (PMID: 18201220) Br J Dermatol. 2003 Oct;149(4):899-901. (PMID: 14616397) N Engl J Med. 2007 Aug 9;357(6):545-52. (PMID: 17687130) J Invest Dermatol. 2008 Dec;128(12):2859-69. (PMID: 18563177) |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Murine-Derived) 0 (Glucocorticoids) 0 (Immunologic Factors) 4F4X42SYQ6 (Rituximab) VB0R961HZT (Prednisone) |
| تواريخ الأحداث: | Date Created: 20130927 Date Completed: 20140402 Latest Revision: 20211021 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC3760947 |
| DOI: | 10.1590/abd1806-4841.20131990 |
| PMID: | 24068143 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1806-4841 |
|---|---|
| DOI: | 10.1590/abd1806-4841.20131990 |